Willyanne DeCormier Plosky

Willyanne DeCormier Plosky

Auto-generated profile, based on publicly available information

Willyanne DeCormier Plosky

Multi‐Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in BMC Public Health
Verified
Journal Article
Open access
PDF file
ESEmily Sonneveldt
Emily Sonneveldt
WPWillyanne DeCormier Plosky
Willyanne DeCormier Plosky
JSJohn Stover
John Stover
A number of data sets show that high parity births are associated with higher child mortality than low parity births. The reasons for this relationship are not clear. In this paper we investigate whether high parity is associated with lower coverage of key health interventions that might lead to increased mortality.

1 December 2015 in Social Science & Medicine
Verified
Journal Article
Closed access
LSLindsay Stark
Lindsay Stark
WPWillyanne DeCormier Plosky
Willyanne DeCormier Plosky
RHRebecca Horn
Rebecca Horn
MCMark Canavera
Mark Canavera

28 November 2019 in African Journal of AIDS Research
Verified
Journal Article
Open access
WPWillyanne DeCormier Plosky
Willyanne DeCormier Plosky
LBLori A Bollinger
Lori A Bollinger
LALily Alexander
Lily Alexander
DCDrew B Cameron
Drew B Cameron
LCLauren N Carroll
Lauren N Carroll
JKJAMES G KAHN
JAMES G KAHN
Consistently defined, accurate, and easily accessible cost data are a valuable resource to inform efficiency analyses, budget preparation, and sustainability planning in global health. The Global H...

28 November 2019 in African Journal of AIDS Research
Verified
Journal Article
Open access
DCDrew B Cameron
Drew B Cameron
MDMohamed Mustafa Diab
Mohamed Mustafa Diab
LCLauren N Carroll
Lauren N Carroll
LBLori A Bollinger
Lori A Bollinger
WPWillyanne DeCormier Plosky
Willyanne DeCormier Plosky
JKJAMES G KAHN
JAMES G KAHN
The past decade has seen a growing emphasis on the production of high-quality costing data to improve the efficiency and cost-effectiveness of global health interventions. The need for such data is...

1 January 2019
Verified
Report
Open access
PDF file
JRJames E. Rosen
James E. Rosen
NBNicole Bellows
Nicole Bellows
LBLori Bollinger
Lori Bollinger
WPWillyanne DeCormier Plosky
Willyanne DeCormier Plosky
MWMichelle Weinberger
Michelle Weinberger
LWLeigh Wynne
Leigh Wynne
Although the development field generally considers social and behavior change interventions essential parts of quality health programs, lack of synthesized information on costs and effectiveness means that decision-makers under-appreciate and under-fund social and behavior change efforts. This business case uses evidence to answer questions about the effectiveness, cost, cost-effectiveness, and return on investment from social and behavior change efforts. To develop this family planning social and behavior change business case, nearly 200 studies were evaluated. All USAID strategic priorities for global health—preventing child and maternal deaths, controlling the HIV/AIDS epidemic, and combating infectious diseases—employ social and behavior change approaches to varying degrees. This is the first in a planned series of complementary, health area-specific business cases.

8 May 2025 in Journal of Empirical Research on Human Research Ethics
Verified
Journal Article
Closed access
ENEmily Nguyen
Emily Nguyen
DADavid Appiah
David Appiah
ANAri Ne'EMan
Ari Ne'EMan
MSMin Shi
Min Shi
BBBarbara E. Bierer
Barbara E. Bierer
DRDavid B. Resnik
David B. Resnik
Background: Unwarranted exclusion of people with uncertain or impaired decision-making capacity from participation in research violates principles of justice and fairness and adversely impacts the health and welfare of these populations. Methods: We conducted a cross-sectional study of institutional review board (IRB) policies for investigators and IRB members at 94 top-funded U.S. research institutions to better understand the guidance they provide to investigators who work with populations that have a wide range in decisional capacity. We collected data from publicly available websites and used deductive and inductive methods to develop our coding framework. Results: We found that 41.5% of institutions had policies that require exclusion of people with uncertain or impaired decision-making capacity unless inclusion is scientifically justified. Only 5.3% had policies that require inclusion of these populations unless exclusion is scientifically justified. Eligibility criteria depended upon the risks of research in 54.3% of policies. Guidance on obtaining consent or assent was provided in 77.7% of policies and 44.7% provided guidance on assessing decision-making capacity. 30.9% of policies required that the IRB include a member who is knowledgeable of the needs and concerns of people with uncertain or impaired decision-making capacity when it reviews research pertaining to that population. Conclusion: Some IRB policies at U.S. research institutions may be unfairly excluding people with uncertain or impaired decision-making from research participation. Institutions should review their IRB policies to ensure that these policies protect adults with uncertain or impaired decision-making capacity from harm but also do not exclude them from research unfairly.